Chromosomal aberrations and SCEs as biomarkers of cancer risk

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Chromosomal aberrations and SCEs as biomarkers of cancer risk. / Norppa, H; Bonassi, S; Hansteen, I-L; Hagmar, L; Strömberg, U; Rössner, P; Boffetta, P; Lindholm, C; Gundy, S; Lazutka, J; Cebulska-Wasilewska, A; Fabiánová, E; Srám, R J; Knudsen, Lisbeth E.; Barale, R; Fucic, A.

In: Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, Vol. 600, No. 1-2, 30.08.2006, p. 37-45.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Norppa, H, Bonassi, S, Hansteen, I-L, Hagmar, L, Strömberg, U, Rössner, P, Boffetta, P, Lindholm, C, Gundy, S, Lazutka, J, Cebulska-Wasilewska, A, Fabiánová, E, Srám, RJ, Knudsen, LE, Barale, R & Fucic, A 2006, 'Chromosomal aberrations and SCEs as biomarkers of cancer risk', Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, vol. 600, no. 1-2, pp. 37-45. https://doi.org/10.1016/j.mrfmmm.2006.05.030

APA

Norppa, H., Bonassi, S., Hansteen, I-L., Hagmar, L., Strömberg, U., Rössner, P., Boffetta, P., Lindholm, C., Gundy, S., Lazutka, J., Cebulska-Wasilewska, A., Fabiánová, E., Srám, R. J., Knudsen, L. E., Barale, R., & Fucic, A. (2006). Chromosomal aberrations and SCEs as biomarkers of cancer risk. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 600(1-2), 37-45. https://doi.org/10.1016/j.mrfmmm.2006.05.030

Vancouver

Norppa H, Bonassi S, Hansteen I-L, Hagmar L, Strömberg U, Rössner P et al. Chromosomal aberrations and SCEs as biomarkers of cancer risk. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 2006 Aug 30;600(1-2):37-45. https://doi.org/10.1016/j.mrfmmm.2006.05.030

Author

Norppa, H ; Bonassi, S ; Hansteen, I-L ; Hagmar, L ; Strömberg, U ; Rössner, P ; Boffetta, P ; Lindholm, C ; Gundy, S ; Lazutka, J ; Cebulska-Wasilewska, A ; Fabiánová, E ; Srám, R J ; Knudsen, Lisbeth E. ; Barale, R ; Fucic, A. / Chromosomal aberrations and SCEs as biomarkers of cancer risk. In: Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 2006 ; Vol. 600, No. 1-2. pp. 37-45.

Bibtex

@article{f1553a82b02648b1a5132cb0be7b610e,
title = "Chromosomal aberrations and SCEs as biomarkers of cancer risk",
abstract = "Previous studies have suggested that the frequency of chromosomal aberrations (CAs), but not of sister chromatid exchanges (SCEs), predicts cancer risk. We have further examined this relationship in European cohorts comprising altogether almost 22,000 subjects, in the framework of a European collaborative project (CancerRiskBiomarkers). The present paper gives an overview of some of the results of the project, especially as regards CAs and SCEs. The results confirm that a high level of CAs is associated with an increased risk of cancer and indicate that this association does not depend on the time between CA analysis and cancer detection, i.e., is obviously not explained by undetected cancer. The present evidence indicates that both chromatid-type and chromosome-type CAs predict cancer, even though some data suggest that chromosome-type CAs may have a more pronounced predictive value than chromatid-type CAs. CA frequency appears to predict cancers at various sites, although there seems to be a particular association with gastrointestinal cancers. SCE frequency does not appear to have cancer predictive value, at least partly due to uncontrollable technical variation. A number of genetic polymorphisms of xenobiotic metabolism, DNA repair, and folate metabolism affect the level of CAs and might collectively contribute to the cancer predictivity of CAs. Other factors that may influence the association between CAs and cancer include, e.g., exposure to genotoxic carcinogens and internal generation of genotoxic species. Although the association between CA level and cancer is seen at the group level, an association probably also exists for the individual, although it is not known if an individual approach could be feasible. However, group level evidence should be enough to support the use of CA analysis as a tool in screening programs and prevention policies in occupational and environmental health.",
keywords = "Chromosome Aberrations, Cohort Studies, Europe, Genetic Markers, Humans, Neoplasms, Polymorphism, Genetic, Risk Assessment, Sister Chromatid Exchange, Xenobiotics",
author = "H Norppa and S Bonassi and I-L Hansteen and L Hagmar and U Str{\"o}mberg and P R{\"o}ssner and P Boffetta and C Lindholm and S Gundy and J Lazutka and A Cebulska-Wasilewska and E Fabi{\'a}nov{\'a} and Sr{\'a}m, {R J} and Knudsen, {Lisbeth E.} and R Barale and A Fucic",
year = "2006",
month = aug,
day = "30",
doi = "10.1016/j.mrfmmm.2006.05.030",
language = "English",
volume = "600",
pages = "37--45",
journal = "Mutation Research Letters",
issn = "0027-5107",
publisher = "Elsevier",
number = "1-2",

}

RIS

TY - JOUR

T1 - Chromosomal aberrations and SCEs as biomarkers of cancer risk

AU - Norppa, H

AU - Bonassi, S

AU - Hansteen, I-L

AU - Hagmar, L

AU - Strömberg, U

AU - Rössner, P

AU - Boffetta, P

AU - Lindholm, C

AU - Gundy, S

AU - Lazutka, J

AU - Cebulska-Wasilewska, A

AU - Fabiánová, E

AU - Srám, R J

AU - Knudsen, Lisbeth E.

AU - Barale, R

AU - Fucic, A

PY - 2006/8/30

Y1 - 2006/8/30

N2 - Previous studies have suggested that the frequency of chromosomal aberrations (CAs), but not of sister chromatid exchanges (SCEs), predicts cancer risk. We have further examined this relationship in European cohorts comprising altogether almost 22,000 subjects, in the framework of a European collaborative project (CancerRiskBiomarkers). The present paper gives an overview of some of the results of the project, especially as regards CAs and SCEs. The results confirm that a high level of CAs is associated with an increased risk of cancer and indicate that this association does not depend on the time between CA analysis and cancer detection, i.e., is obviously not explained by undetected cancer. The present evidence indicates that both chromatid-type and chromosome-type CAs predict cancer, even though some data suggest that chromosome-type CAs may have a more pronounced predictive value than chromatid-type CAs. CA frequency appears to predict cancers at various sites, although there seems to be a particular association with gastrointestinal cancers. SCE frequency does not appear to have cancer predictive value, at least partly due to uncontrollable technical variation. A number of genetic polymorphisms of xenobiotic metabolism, DNA repair, and folate metabolism affect the level of CAs and might collectively contribute to the cancer predictivity of CAs. Other factors that may influence the association between CAs and cancer include, e.g., exposure to genotoxic carcinogens and internal generation of genotoxic species. Although the association between CA level and cancer is seen at the group level, an association probably also exists for the individual, although it is not known if an individual approach could be feasible. However, group level evidence should be enough to support the use of CA analysis as a tool in screening programs and prevention policies in occupational and environmental health.

AB - Previous studies have suggested that the frequency of chromosomal aberrations (CAs), but not of sister chromatid exchanges (SCEs), predicts cancer risk. We have further examined this relationship in European cohorts comprising altogether almost 22,000 subjects, in the framework of a European collaborative project (CancerRiskBiomarkers). The present paper gives an overview of some of the results of the project, especially as regards CAs and SCEs. The results confirm that a high level of CAs is associated with an increased risk of cancer and indicate that this association does not depend on the time between CA analysis and cancer detection, i.e., is obviously not explained by undetected cancer. The present evidence indicates that both chromatid-type and chromosome-type CAs predict cancer, even though some data suggest that chromosome-type CAs may have a more pronounced predictive value than chromatid-type CAs. CA frequency appears to predict cancers at various sites, although there seems to be a particular association with gastrointestinal cancers. SCE frequency does not appear to have cancer predictive value, at least partly due to uncontrollable technical variation. A number of genetic polymorphisms of xenobiotic metabolism, DNA repair, and folate metabolism affect the level of CAs and might collectively contribute to the cancer predictivity of CAs. Other factors that may influence the association between CAs and cancer include, e.g., exposure to genotoxic carcinogens and internal generation of genotoxic species. Although the association between CA level and cancer is seen at the group level, an association probably also exists for the individual, although it is not known if an individual approach could be feasible. However, group level evidence should be enough to support the use of CA analysis as a tool in screening programs and prevention policies in occupational and environmental health.

KW - Chromosome Aberrations

KW - Cohort Studies

KW - Europe

KW - Genetic Markers

KW - Humans

KW - Neoplasms

KW - Polymorphism, Genetic

KW - Risk Assessment

KW - Sister Chromatid Exchange

KW - Xenobiotics

U2 - 10.1016/j.mrfmmm.2006.05.030

DO - 10.1016/j.mrfmmm.2006.05.030

M3 - Journal article

C2 - 16814813

VL - 600

SP - 37

EP - 45

JO - Mutation Research Letters

JF - Mutation Research Letters

SN - 0027-5107

IS - 1-2

ER -

ID: 137758483